-
Compass Therapeutics (CMPX) enters the second half of 2026 in a strong financial position
NASDAQ: $CMPX Compass Therapeutics enters the second half of 2026 in a strong financial position, though its stock has recently experienced significant volatility following the long-awaited data readout for its lead program. Cash Runway As of the most recent financial updates in early 2026, Compass Therapeutics is exceptionally well-capitalized for a clinical-stage biotech: 2026 Pipeline…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
Hoth Therapeutics Reports Significant Initial Results in Novel Cancer Therapy Trial
NASDAQ: $HOTH A recent press release from PR Newswire highlights exciting early data from Hoth Therapeutics regarding their ongoing clinical study involving a novel treatment approach for cancer patients whose tumors express the Epidermal Growth Factor Receptor (EGFR). The announcement, specifically concerning the open-label pharmacokinetic (PK) cohort of the study, signals a promising step forward…